Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
Clinical trial NCT06746961 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06746961
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-01
- Primary completion
- 2026-07-01
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.